参考文献/References:
[1]Magri MC,Alvarez MSM,Iogi AA,et al.Study of CXCL9-11 gene polymorphisms in liver fibrosis among patients with chronic hepatitis C[J].Pathog Dis,2021,79(3):ftab007.[2]陈艳,郭朋.活血化瘀法治疗HF的理论基础及作用机制探讨[J].中西医结合肝病志,2019,29(4):299-300.[3]Nordstr?觟m A,Bergman J,Bj?觟rk S,et al.A multiple risk factor program is associated with decreased risk of cardiovascular disease in 70-year-olds: A cohort study from Sweden[J].PLoS Med,2020,17(6):e1003135.[4]Cigrovski Berkovic M,Virovic-Jukic L,Bilic-Curcic I,et al.Post-transplant diabetes mellitus and preexisting liver disease-a bidirectional relationship affecting treatment and management[J].World J Gastroenterol,2020,26(21):2740-2757.[5]徐玉玲,罗宏伟,丁沛.鳖甲煎丸对慢性乙型肝炎早期肝硬化患者肿瘤坏死因子-α和基质金属蛋白酶-2的影响[J].世界中医药,2017,12(9):2077-2079,2083.[6]郭涛.当归补血汤及其组分配伍影响肝血管新生的抗肝纤维化作用评价及机制研究[D].上海:上海中医药大学,2014.[7]陶艳艳,陈园,陈高峰,等.当归补血汤不同配比组方的抗肝纤维化作用[J].上海中医药大学学报,2008(1):40-44.[8]罗军.肝纤维化从瘀论治及“复肝丸”的作用机制浅探[J].国医论坛,2008,23(4):48-49.[9]杨倩,冯玉彦,蒋树林.姚希贤瘀血论治慢性肝纤维化经验[J].中华中医药杂志,2007,22(3):168-171.[10]邢华旭,柴根旺.活血化瘀法在慢性肝病治疗中的应用体会[J].山西中医学院学报,2007(5):44-46.[11]陈一凡,孙会卓,罗慜婧,等.“茵陈-郁金”药对配伍对HF模型大鼠作用效果研究[J].贵阳中医学院学报,2018,40(2):13-15．[12]Hu GY,Yang P,Zeng Y,et al.Danggui Buxue decoction promotes angiogenesis by up-regulation ofVEGFR1/2expressions and down-regulation of s VEGFR1/2 expression in myocardial infarction rat [J].J Chin Med Assoc,2018,81(1):37-46.[13]肖志鸿,吴丽,陈国良.陈国良教授以扶正祛邪法诊治肝纤维化的经验[J].光明中医,2018,33(7):927-929.[14]王德才,黎梓旺,秦绪花,等.从仲景鳖甲煎丸方谈肝纤维化从络病论治[J].江西中医学院学报,2011,23(1):23-24,38.[15]国家药典委员会.中国药典:2015年版:一部[S].北京:中国医药科技出版社,2015:152-153,302-303.[16]顾志荣,马天翔,祁梅,等.黄芪-当归药对配伍前后HPLC指纹图谱及主要化学成分变化[J].中国现代应用药学,2020,37(3):275- 281.[17]许燕妮,吴江峰,丁舸.当归-黄芪药对在方剂配伍中的意义[J].江西中医药,2018,49(7):73-74. [18]Sommerhalder C,Cummins CB,Wang X,et al.HJC0416 Attenuates Fibrogenesis in Activated Hepatic Stellate Cells via STAT3 and NF-κB Pathways[J].J Surg Res,2021(261):334-342. [19]Wu X,Dong W,Zhang T,et al.Epiregulin (EREG) and Myocardin Related Transcription Factor A (MRTF-A) Form a Feedforward Loop to Drive Hepatic Stellate Cell Activation[J].Front Cell Dev Biol,2021(8):591246. [20]Jang SY,Tak WY,Park SY,et al.Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases[J].Ann Lab Med,2021,41(3):302-309.[21]王飞虾.千层纸素A下调LDH-A阻断HSC有氧糖酵解依赖性收缩抗肝纤维化的机制研究[D].南京:南京中医药大学,2019.[22]Dong H,Guo H,Liang Y,et al.Astragaloside IV synergizes with ferulic acid to suppress hepatic stellate cells activation in vitro[J].Free Radic Res,2017(51):167-178.[23]Roehlen N,Crouchet E,Baumert TF.Liver Fibrosis:Mechanistic concepts and therapeutic perspectives[J].Cells,2020,9(4):875.[24]Guo T,Liu ZL,Zhao Q,et al.A combination of astragaloside I, levistilide A and calycosin exerts anti- liver fibrosis effects in vitro and in vivo[J].Acta Pharmacol Sin,2018,39(9):1483-1492. [25]Guo T,Liu Z L,Zhao Q,et al.A combination of astragaloside I,levistilide A and calycosin exertsanti-liver fibrosis effects in vitro and in vivo[J].Acta Pharmacol Sin,2018,39(9):1483-1492.[26]王素霞.不同方法炮制当归化学成分分析[J].实用中医杂志,2020,36(6):818-819.[27]霍礼超,李梦丽,乔成栋.当归多糖对缺氧-复氧损害H9c2心肌细胞的保护作用[J].岭南心血管病杂志,2019,25(5):579-585.[28]彭宇,赵博琛,康倩,等.当归超临界提取物和酚酸类成分配伍预防结直肠癌作用研究[J].中国中药杂志,2018, 43(6):1235-1240.[29]孙丽丽,白海英,郑文惠,等.基于UHPLC-Q-TOF-MS的当归补血汤治疗2型糖尿病小鼠的代谢组学研究[J].中国中药杂志,2020,45(3):636-644.[30]郭玲,李惠珍,魏亚君.阿魏酸对大鼠HF过程中肝细胞的保护作用及其可能机制[J].临床和实验医学杂志,2019,18(4):357-361.[31]孙璐,黄水清,马文静,等.当归补血汤对RAW264.7细胞的TNF-α、ICAM-1表达的作用[J].北京中医药大学学报,2010,33(1):33-35. [32]尚伟庆.黄芪当归合剂对肾病综合征患者肾功能、炎症机制及疗效的影响[J].中华中医药学刊,2017,35(5):1339-1341. [33]覃倩华,杨萍,李英,等.黄芪当归配伍对免疫功能影响的初步研究[J].江西中医学院学报,2013,25(4):59-62.[34]徐婷,麦葭沂,向俊,等.“黄芪-当归”药对主要活性成分的网络药理学研究[J].中药材,2017,40(9):2195-2201.[35]袁颖,郭忻,金素安,等.黄芪当归不同配伍对气虚血瘀证大鼠血液流变学及血清干扰素-γ、白细胞素-4的影响[J].中国中医药信息杂志,2013,20(11):44-46. [36]刘雅,张海港,张翼冠,等.当归补血汤对气虚血瘀大鼠免疫功能及相关基因的调控[J].中药药理与临床,2009,25(5):10-13.[37]王时光,杨帆,梁国庆,等.当归补血汤对心肌缺血模型大鼠心肌组织氧化应激的影响[J].时珍国医国药,2016,27(8):1850-1852. [38]秦雪梅,李爱平,刘月涛,等.多效中药定向药效成分研究策略[J].中草药,2017(48):847-852.[39]顾志荣,马天翔,祁梅,等.黄芪-当归药对配伍前后HPLC指纹图谱及主要化学成分变化[J].中国现代应用药学,2020,37(3):275-281.[40]黄丽萍,陈耀辉,吴素芬,等.当归补血汤含药血清对血虚小鼠骨髓造血功能的影响[J].中药药理与临床,2014,30(2):18-20.
相似文献/References:
[1]王艳欣,孟庆华,朱跃科.非侵入性检查方法评价肝纤维化的研究进展[J].医学信息,2018,31(03):40.[doi:10.3969/j.issn.1006-1959.2018.03.014]
WANG Yan-xin,MENG Qing-hua,ZHU Yue-ke.Progress in Evaluation of Liver Fibrosis by Non-invasive Methods[J].Medical Information,2018,31(08):40.[doi:10.3969/j.issn.1006-1959.2018.03.014]
[2]李顶春,李 武.Wnt信号通路与肝纤维化[J].医学信息,2018,31(09):4.[doi:10.3969/j.issn.1006-1959.2018.09.002]
LI Ding-chun,LI Wu.Wnt Signaling Pathway and Hepatic Fibrosis[J].Medical Information,2018,31(08):4.[doi:10.3969/j.issn.1006-1959.2018.09.002]
[3]艾迎春,迟男男,杜景峰,等.芪参二莲汤对肝纤维化大鼠基质金属蛋白酶-1及
抑制因子的影响[J].医学信息,2018,31(15):140.[doi:10.3969/j.issn.1006-1959.2018.15.045]
AI Ying-chun,CHI Nan-nan,DU Jing-feng,et al.Effects of Qishenerlian Decoction on Matrix Metalloproteinase-1 and Its Inhibitory Factors in Rats with Hepatic Fibrosis[J].Medical Information,2018,31(08):140.[doi:10.3969/j.issn.1006-1959.2018.15.045]
[4]董 朴,蔡福景,张 东,等.胆维他片对肝纤维化大鼠肝中抗氧化体系的影响[J].医学信息,2019,32(18):138.[doi:10.3969/j.issn.1006-1959.2019.18.046]
DONG Pu,CAI Fu-jing,ZHANG Dong,et al.Effect of Danweiita Tablet on Antioxidant System in Liver of Rats with Hepatic Fibrosis[J].Medical Information,2019,32(08):138.[doi:10.3969/j.issn.1006-1959.2019.18.046]
[5]陈 越,彭 莉.黄芪对细胞毒素相关蛋白A诱导的大鼠系膜细胞外基质分泌的影响[J].医学信息,2022,35(15):104.[doi:10.3969/j.issn.1006-1959.2022.15.023]
CHEN Yue,PENG Li.Effect of Astragalus Membranaceus on CagA-induced Extracellular Matrix Secretion of Rat Mesangial Cells[J].Medical Information,2022,35(08):104.[doi:10.3969/j.issn.1006-1959.2022.15.023]
[6]皮青文.恩替卡韦抗病毒治疗对慢性乙肝肝硬化患者肝功能及肝硬化程度的影响[J].医学信息,2022,35(15):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
PI Qing-wen.Effect of Entecavir Antiviral Therapy on Liver Function and Degree of Liver Cirrhosis in Patients with Chronic Hepatitis B Cirrhosis[J].Medical Information,2022,35(08):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
[7]林思萍,龚先琼.中药单体调控TGF-β1/Smads信号通路抗纤维化的研究[J].医学信息,2019,32(21):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
LIN Si-ping,GONG Xian-qiong.Study on Anti-Fibrosis of TGF-β1/Smads Signaling Pathway Regulated by Chinese Medicine Monomer[J].Medical Information,2019,32(08):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
[8]张小雨,严 艳.自身免疫性肝炎合并自身免疫性疾病的特征研究[J].医学信息,2020,33(02):89.[doi:10.3969/j.issn.1006-1959.2020.02.024]
ZHANG Xiao-yu,YAN Yan.Study on the Characteristics of Autoimmune Hepatitis Combined with Autoimmune Diseases[J].Medical Information,2020,33(08):89.[doi:10.3969/j.issn.1006-1959.2020.02.024]
[9]邹克平.超声实时剪切波弹性成像对血吸虫病肝纤维化的诊断效能分析[J].医学信息,2022,35(18):150.[doi:10.3969/j.issn.1006-1959.2022.18.042]
ZOU Ke-ping.Analysis of Diagnostic Efficacy of Ultrasound Shear Wave Elastography in Schistosomiasis Liver Fibrosis[J].Medical Information,2022,35(08):150.[doi:10.3969/j.issn.1006-1959.2022.18.042]
[10]郭 冶,卢凤美,刘东璞.肝纤维化发病机制及大黄酸对肝纤维化的作用[J].医学信息,2020,33(12):27.[doi:10.3969/j.issn.1006-1959.2020.12.010]
GUO Ye,LU Feng-mei,LIU Dong-pu.The Pathogenesis of Hepatic Fibrosis and the Effect of Rhein on Hepatic Fibrosis[J].Medical Information,2020,33(08):27.[doi:10.3969/j.issn.1006-1959.2020.12.010]